EAEU Registration: Reference State and Recognizing State Mechanism

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Union registration follows a reference state plus recognizing states structure: the applicant selects one reference state (референтное государство), submits the registration dossier there, and undergoes expert review organized by that state’s competent authority; the applicant then selects several recognizing states (государство признания) that accept the review conclusions. On completion, the device enters the Union unified register and may circulate within the selected member states. The competent authority for the Russian Federation is RZN, with technical expert review performed by its subordinate expert institutions.

This architecture gives manufacturers flexibility in where the review burden is placed, but it also introduces coordination obligations that national procedures do not have. Success depends less on the strength of a single dossier than on the alignment between the reference-state review and the expectations of each recognizing state. Planning both stages from the start — rather than treating recognition as an afterthought — is what separates timely multi-market access from stalled certificates.

The mechanism also assigns the applicant two structural roles that must be filled early: a local representative in the reference state who can interact with the authority and expert institutions, and corresponding arrangements in each recognizing state. Language is a practical dimension of both roles — the dossier, correspondence and expert responses operate in Russian, and in the languages of the other member states where required. Manufacturers who underinvest in these representation and translation arrangements typically discover the shortfall mid-procedure, when a recognizing state requests supplementary material in its own language and the clock is already running. Budgeting for representation, translation and local coordination as first-class project costs, rather than ancillary items, is part of a realistic timeline.

2. Legal basis

The reference-and-recognition mechanism is defined by the EAEU founding agreement and implemented through a set of Commission decisions covering procedure, evidence, classification and labeling. The table below maps the relevant instruments.

Legal actReference / numberDateProvisions
Agreement on Unified Principles and Rules for the Circulation of Medical Devices in the EAEUAgreementDecember 23, 2014Article 4 (registration and circulation), Article 7 (circulation mark)
Decision of the Eurasian Economic Commission on the rules of registration and expert review of medical devicesЕЭК Decision No. 46February 12, 2016Registration and expert review procedure; reference state and recognizing state mechanism
Decision of the Eurasian Economic Commission on classification rules by potential riskЕЭК Decision No. 173December 22, 2015 (as amended by Amendment No. 18 of February 18, 2025)Classification rules
Decision of the Eurasian Economic Commission on the special circulation mark for medical devices in the Union marketЕЭК Decision No. 26February 12, 2016Mark requirements
Government resolution of the Russian Federation on national registration rules for medical devicesПП РФ No. 1684November 30, 2024National pathway for comparison

3. Expert insights

Insight one: the reference state is the anchor of review quality. The choice of reference state determines the pace of review and the focus areas of the expert institution, and it also influences how readily the recognizing states accept the conclusions. Where Russia is chosen as the reference state, its expert institutions apply review emphases in sterile devices, software and IVD that share a common origin with the national pathway, which tends to favor manufacturers already adapted to Russian requirements. Conversely, a reference state chosen purely for convenience, without regard to where the product will actually be sold, can create friction at the recognition stage.

Insight two: recognizing states do not automatically approve. A recognizing state’s expert institution may raise differing opinions, and it may refuse to recognize the reference state’s review conclusions. Once a divergence appears, the Union registration may end up valid only within the reference state. A multi-market launch plan must therefore reserve time for communication with each recognizing state, and the commercial sequencing of market entries should not assume that all selected states go live on the same day. Practical estimate: treat each recognizing state as its own mini-project with its own review clock.

Insight three: after certification, the result documents and the home-country legal framework are no longer the same set. Upon obtaining the certificate, the unified circulation mark under Decision No. 26 is applied, and post-market surveillance follows the Union rules of Decision No. 174 — not Russian Order No. 540н. This switch must be reflected explicitly in the quality management system documentation, including vigilance procedures, periodic reporting formats and the identity of the authorities to be notified, so that the surveillance system matches the legal basis of the registration actually held.

A final point concerns market sequencing within the certificate. Because circulation is limited to the selected member states, the list of recognizing states chosen at application effectively becomes the commercial map of the launch. States can matter for different reasons: market size, reimbursement structure, or simply where the distributor network already exists. Reviewing the recognizing-state list against the commercial plan before submission — rather than defaulting to all five states — aligns the regulatory footprint with real sales intent. Adding a member state later involves separate procedures, so the initial selection should be treated as a strategic decision with a documented rationale, revisited at each portfolio review as market conditions evolve.

4. Practical recommendations

  1. Select the reference state by weighing three factors together: the local expert institution’s familiarity with the product category, the communication capability of your local representative there, and the priority ranking of your target markets. Document the rationale, because the choice shapes the whole project timeline and is costly to reverse once the dossier is submitted.
  2. Schedule the recognizing-state communication plan in parallel, not after the reference-state conclusions arrive. Early contact clarifies each state’s expectations regarding supplementary data and translations, and prevents the recognition stage from becoming the critical path of the launch calendar.
  3. After certification, switch the mark, QMS documentation and surveillance processes to Union rules in one coordinated change. Run an internal gap review against Decision No. 174 requirements and Decision No. 26 mark specifications before the first placing on the market under the Union certificate.

5. Verification checklist

  • □ The reference state has been selected and its competent authority and expert institution confirmed
  • □ The list of recognizing states has been drawn up and contacts obtained for each
  • □ The registration dossier has been compiled per Decision No. 46, including a Russian-language (and, where necessary, member-state language) version
  • □ A draft of the unified circulation mark (Decision No. 26) has been designed
  • □ The post-market system has been switched to the Union surveillance rules of Decision No. 174

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers entering the Russian market with end-to-end regulatory services covering both registration pathways: national registration under ПП РФ No. 1684, including route selection among clauses 63, 87 and 101, and EAEU registration under ЕЭК Decision No. 46, together with classification strategy support under Decision No. 173 as amended. Our team helps define the optimal route for each registration unit, prepare dossiers and testing plans, coordinate with RZN and expert institutions, and track transition deadlines through December 31, 2027. For tailored support on Russia market entry, pathway selection and dossier preparation, contact GRZAN at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail